Typewriter Therapeutics Raises $56M for In Vivo CAR T

Typewriter Therapeutics emerged from stealth on September 2, 2026 with a $56M Series A to develop an all-RNA, non-viral gene-insertion platform for in vivo CAR T medicines and genetic liver diseases. AN Venture Partners and RA Capital Management led the financing, with ANRI, Gemseki, and SBI US Gateway Fund participating.

The Cambridge-and-Tokyo biotechnology company is trying to move a difficult part of cell therapy from the factory into the patient. Instead of collecting T cells, engineering them outside the body, testing them, and returning them for infusion, Typewriter is designing RNA medicines that could insert a therapeutic gene directly into a patient’s cells. The promise is simpler access and durable expression. The evidence remains preclinical, with the company planning its first nonhuman-primate studies for late 2026.

What Typewriter Therapeutics Announced

The $56M Series A announcement named AN Venture Partners and RA Capital Management as co-leads. ANRI, Gemseki, and SBI US Gateway Fund also participated. Typewriter did not disclose a valuation, ownership percentages, individual check sizes, or a verified lifetime-funding total.

The financing coincides with several leadership appointments. Matthew Stanton, PhD, became CEO and a board director. Leanne Peiser, DPhil, joined as CSO. Former Pfizer CSO Mikael Dolsten, MD, PhD, joined the board as an independent director, and Stanley R. Riddell, MD, joined the scientific advisory board.

Typewriter says the capital will extend proof-of-concept work established in humanized mouse models and support selection of its first in vivo CAR T development candidate. The company’s initial development focus covers in vivo CAR T and genetic liver diseases. Its first nonhuman-primate studies are planned for late 2026, making those studies a near-term test of delivery, insertion, durability, and safety beyond rodent models.

How Typewriter’s All-RNA Gene Insertion Works

Typewriter’s science platform is based on the R2 retrotransposon, a natural gene-insertion system that uses target-primed reverse transcription, or TPRT. The company’s academic co-founders helped discover the R2 family and define the mechanism over decades of research.

The therapy uses 2 RNA components delivered inside a lipid nanoparticle. One mRNA produces the R2 protein. A second RNA carries the therapeutic gene and flanking sequences designed to recruit that protein. Inside the cell, the components assemble into a complex intended to insert the gene at a conserved site within the 28S ribosomal DNA locus. The RNA machinery then degrades, leaving the inserted gene at the intended location.

That design creates several important distinctions. The system is non-viral, aims for site-specific rather than semi-random insertion, and is intended to install a full working gene instead of making a small edit. Because the inserted gene becomes part of genomic DNA, Typewriter expects the effect to persist as cells divide. The company also argues that an RNA-and-lipid-nanoparticle approach could reduce immunogenicity and support repeat dosing, but those benefits remain development goals rather than clinical outcomes.

Why In Vivo CAR T Changes the Manufacturing Question

Conventional autologous CAR T therapy requires a patient’s T cells to be collected and engineered outside the body before reinfusion. That process can involve specialized manufacturing, quality testing, shipping, scheduling, and waiting during serious disease. In vivo CAR T developers are trying to perform more of the engineering directly inside the patient.

The market has attracted heavy pharmaceutical interest because a successful in vivo approach could simplify delivery and reach more patients. Fierce Biotech’s 2026 market reporting documented a broader industry movement toward in vivo CAR T, including multiple acquisitions and partnerships. That context supports investor interest, but it does not reduce the scientific burden. A platform must deliver into the right cells, control where and how the gene integrates, produce the desired activity, and demonstrate a safety profile that survives clinical scrutiny.

Typewriter’s specific wager is that durable gene insertion can be achieved with RNA without relying on a viral vector or creating double-stranded DNA breaks. If the platform works as designed, the patient’s own T cells could become the manufacturing site. The commercial value would come from simplifying a treatment pathway that currently carries time, cost, and logistical complexity at nearly every handoff.

The People and Research Behind Typewriter

Typewriter was founded in February 2022 and operates in Cambridge, Massachusetts and Tokyo, Japan. Its current team page traces the scientific foundation to Haruhiko Fujiwara, PhD, of the University of Tokyo and Tom Eickbush, PhD, of the University of Rochester. Both are listed as academic co-founders and advisors. Jun Zhou, PhD, is a founder and vice president of discovery and global operations. Kei Endo, PhD, Victor Stone, MD, and Jim Collins, PhD, are also listed among the scientific co-founders and advisors.

CEO Matthew Stanton previously served as a venture partner at Raven, RA Capital’s healthcare incubator. Before that, he spent 7 years at Generation Bio as CTO and then CSO, following work as vice president and head of chemistry at Moderna Therapeutics. Typewriter says his Moderna team identified lipid nanoparticles used in vaccine development and helped move early mRNA vaccines toward clinical development.

CSO Leanne Peiser brings more than 20 years of research and development experience in immunology, immunotherapy, and cellular therapy. She most recently served as executive director of translational research for cellular therapy at Bristol Myers Squibb. Typewriter’s leadership team also includes Ari Friedland, PhD, vice president of research, and Mayu Yoshikawa, PhD, president of Typewriter Japan.

What the $56M Must Prove

The Series A moves Typewriter from quiet platform construction into a visible development race. The company has disclosed proof of concept in humanized mouse models, not human efficacy or safety data. Its planned nonhuman-primate studies therefore matter because they can test whether the delivery and insertion system behaves reliably in biology closer to humans.

Typewriter must show more than successful gene insertion. It will need evidence that the payload reaches the intended cells, lands at the intended genomic site, produces durable therapeutic expression, can be re-dosed when necessary, and avoids unwanted immune or genomic effects. Those requirements are especially important for in vivo CAR T, where simpler administration matters only if control survives the move from a manufacturing suite into the patient.

The company’s cross-border structure also carries a useful signal. Typewriter is translating scientific work that originated in Japan into a biotechnology company built across Tokyo and Cambridge, with U.S. venture capital and experienced RNA and cell-therapy operators around it. The round is funding both a technology platform and a handoff between academic discovery, company formation, preclinical evidence, and eventual clinical development.

Typewriter has chosen a name that makes the ambition sound almost clean: write the gene where it belongs. The next stage will be less literary. It will be measured in delivery, insertion profiles, toxicology, durability, repeat dosing, and the patient evidence required to turn a precise molecular sentence into a medicine.